Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
2.36
Dollar change
+0.25
Percentage change
11.85
%
Index- P/E- EPS (ttm)-1.59 Insider Own13.83% Shs Outstand20.22M Perf Week71.01%
Market Cap47.72M Forward P/E- EPS next Y-0.52 Insider Trans-0.90% Shs Float17.42M Perf Month59.46%
Income-28.77M PEG- EPS next Q-0.40 Inst Own45.34% Short Float0.32% Perf Quarter74.81%
Sales0.00M P/S- EPS this Y14.78% Inst Trans6.47% Short Ratio0.02 Perf Half Y38.82%
Book/sh1.40 P/B1.69 EPS next Y67.35% ROA-64.03% Short Interest0.05M Perf Year110.71%
Cash/sh1.53 P/C1.55 EPS next 5Y39.60% ROE-84.71% 52W Range0.76 - 3.79 Perf YTD84.37%
Dividend Est.- P/FCF- EPS past 5Y56.20% ROI-97.53% 52W High-37.73% Beta1.43
Dividend TTM- Quick Ratio3.89 Sales past 5Y2333.84% Gross Margin- 52W Low210.53% ATR (14)0.33
Dividend Ex-Date- Current Ratio3.89 EPS Y/Y TTM25.16% Oper. Margin0.00% RSI (14)70.29 Volatility39.65% 14.60%
Employees30 Debt/Eq0.14 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price7.25
Option/ShortYes / No LT Debt/Eq0.04 EPS Q/Q20.98% Payout- Rel Volume0.29 Prev Close2.11
Sales Surprise- EPS Surprise-0.83% Sales Q/Q- EarningsNov 09 AMC Avg Volume2.95M Price2.36
SMA2043.23% SMA5062.37% SMA20067.98% Trades Volume857,456 Change11.85%
Date Action Analyst Rating Change Price Target Change
Mar-18-24Initiated Leerink Partners Outperform $6
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Mar-13-24 12:09PM
Mar-12-24 06:32AM
06:30AM
Jan-02-24 04:05PM
Nov-22-23 08:00AM
04:32PM Loading…
Nov-09-23 04:32PM
04:05PM
Nov-02-23 08:00AM
Oct-19-23 08:00AM
Sep-20-23 07:00AM
Sep-13-23 08:00AM
Sep-05-23 08:00AM
Aug-24-23 07:33PM
Aug-23-23 01:04PM
08:00AM
04:43PM Loading…
Aug-08-23 04:43PM
04:05PM
Aug-02-23 08:00AM
Jul-18-23 08:00AM
Jun-27-23 08:00AM
Jun-23-23 08:00AM
Jun-20-23 08:00AM
Jun-12-23 08:00AM
May-16-23 08:00AM
May-11-23 04:18PM
04:05PM
Apr-13-23 08:00AM
Apr-12-23 04:05PM
Mar-23-23 04:52PM
04:05PM
08:00AM Loading…
Feb-09-23 08:00AM
Jan-13-23 04:05PM
Jan-09-23 06:01AM
Dec-12-22 08:00AM
Nov-29-22 05:43PM
08:00AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 08:00AM
Sep-13-22 11:58AM
Sep-12-22 11:14AM
08:00AM
Sep-02-22 04:05PM
Aug-11-22 04:10PM
Aug-04-22 08:00AM
Jun-21-22 08:00AM
Jun-13-22 08:00AM
Jun-02-22 08:00AM
May-17-22 04:30PM
07:00AM
May-12-22 04:05PM
10:20AM
May-11-22 08:00AM
May-05-22 04:05PM
Mar-24-22 12:03PM
08:00AM
Mar-10-22 04:05PM
Mar-03-22 05:15PM
Feb-24-22 08:00AM
Feb-10-22 04:30PM
Jan-26-22 10:00AM
Jan-20-22 05:18PM
Jan-19-22 09:38AM
Jan-04-22 08:00AM
Dec-03-21 08:30AM
Dec-01-21 08:30AM
Nov-30-21 05:23PM
Nov-24-21 04:05PM
Nov-10-21 05:45PM
04:05PM
Nov-03-21 05:15PM
Oct-28-21 03:05PM
Oct-13-21 03:11PM
12:27PM
07:27AM
Oct-12-21 04:05PM
Sep-30-21 04:45PM
Sep-09-21 04:40PM
Sep-06-21 02:33PM
Aug-10-21 05:55PM
04:05PM
Aug-03-21 05:15PM
Jun-30-21 09:33AM
Jun-25-21 01:38PM
07:05AM
Jun-21-21 07:00AM
Jun-11-21 08:56AM
May-21-21 10:47AM
08:07AM
May-14-21 04:07PM
May-13-21 05:35PM
04:07PM
03:15PM
May-06-21 03:01PM
May-03-21 09:25AM
08:00AM
Apr-15-21 08:07AM
Apr-07-21 08:07AM
Mar-10-21 04:03AM
Mar-09-21 04:07PM
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagan Joseph PChief Executive OfficerJan 18 '24Sale1.1914,58017,35957,112Jan 18 08:22 PM
CALSADA CRISPINAChief Financial OfficerJan 18 '24Sale1.195,4686,5105,782Jan 18 08:24 PM
Aker Christopher RaySr. VP & General CounselJan 18 '24Sale1.195,4686,51010,056Jan 18 08:23 PM